Claims for Patent: 5,582,823

Summary for Patent: 5,582,823

Title:	Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (\"hpG-CSF\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s):	Souza; Lawrence M. (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	08/452,135
Patent Claims:	1. A method for treating a mammal for bacterial inflammation comprising an effective amount of a hpG-CSF polypeptide having an amino acid sequence selected from the group consisting of: ##STR18## and analogs thereof wherein one or more of the cysteine residues at positions 17, 36, 42, 64 and 74 are replaced by serine. 2. A method for providing granulocytopoietic therapy to a mammal comprising administering an effective amount of a hpG-CSF polypeptide having an amino acid sequence selected from the group consisting of: and analogs thereof wherein one or more cysteines residues located at positions 17, 36, 42, 64 and 74 are replaced by serine. 3. A method of claim 2 wherein said therapy is in conjunction with chemotherapy. 4. A method of claim 2 wherein said therapy is in conjunction with radiation therapy. 5. A method of claim 2 wherein said therapy is in conjunction with removal of blood progenitor cells.

Details for Patent 5,582,823

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	February 20, 1991		2015-05-26
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	June 28, 2000		2015-05-26
Amgen Inc.	NEULASTA	pegfilgrastim	Injection	125031	January 31, 2002		2015-05-26
Amgen Inc.	NEULASTA ONPRO	pegfilgrastim	Injection	125031	December 23, 2014		2015-05-26

International Patent Family for US Patent 5,582,823

Country	Patent Number	Estimated Expiration
South Africa	866412
World Intellectual Property Organization (WIPO)	8701132
United States of America	6716606
United States of America	6379661
United States of America	6004548
United States of America	5830705
United States of America	5676941